loading
Voyager Therapeutics Inc stock is traded at $5.27, with a volume of 117.23K. It is down -1.76% in the last 24 hours and down -31.26% over the past month. Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$5.36
Open:
$5.35
24h Volume:
117.23K
Relative Volume:
0.21
Market Cap:
$292.79M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
2.3216
EPS:
2.27
Net Cash Flow:
$-28.66M
1W Performance:
-15.34%
1M Performance:
-31.26%
6M Performance:
-37.61%
1Y Performance:
-21.52%
1-Day Range:
Value
$5.19
$5.42
1-Week Range:
Value
$5.19
$6.1499
52-Week Range:
Value
$5.19
$11.72

Voyager Therapeutics Inc Stock (VYGR) Company Profile

Name
Name
Voyager Therapeutics Inc
Name
Phone
857-259-5340
Name
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Name
Employee
162
Name
Twitter
@VoyagerTx
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
VYGR's Discussions on Twitter

Compare VYGR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
VYGR 5.27 292.79M 163.78M 25.88M -28.66M 2.27
VRTX 446.95 115.74B 10.63B -479.80M -1.35B 13.33
REGN 742.11 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 588.63 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 250.00 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.98 24.49B 3.30B -501.07M 1.03B 11.54

Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades

Date Action Analyst Rating Change
May-10-23 Initiated Truist Buy
Mar-10-23 Initiated Oppenheimer Outperform
Oct-07-21 Upgrade Robert W. Baird Neutral → Outperform
Feb-26-21 Downgrade Robert W. Baird Outperform → Neutral
Feb-03-21 Downgrade BTIG Research Buy → Neutral
Feb-03-21 Downgrade Wedbush Outperform → Neutral
Dec-24-20 Downgrade Cantor Fitzgerald Overweight → Neutral
Dec-23-20 Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20 Downgrade Oppenheimer Outperform → Perform
Nov-10-20 Downgrade Raymond James Strong Buy → Outperform
Nov-10-20 Downgrade Wells Fargo Overweight → Equal Weight
Mar-19-20 Initiated The Benchmark Company Buy
Feb-06-20 Initiated Oppenheimer Outperform
Nov-15-18 Upgrade Raymond James Outperform → Strong Buy
Sep-10-18 Resumed BTIG Research Buy
Sep-10-18 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-18 Initiated H.C. Wainwright Buy
Mar-12-18 Downgrade Evercore ISI Outperform → In-line
Mar-12-18 Downgrade Wedbush Outperform → Neutral
Feb-02-18 Initiated Morgan Stanley Overweight
Nov-28-17 Resumed Piper Jaffray Overweight
Oct-31-17 Initiated Robert W. Baird Outperform
Oct-27-17 Initiated Canaccord Genuity Buy
Oct-23-17 Reiterated Stifel Buy
Oct-12-17 Initiated Raymond James Outperform
Aug-17-17 Initiated Evercore ISI Outperform
Jul-28-17 Resumed Stifel Buy
View All

Voyager Therapeutics Inc Stock (VYGR) Latest News

pulisher
Nov 20, 2024

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease - GlobeNewswire

Nov 20, 2024
pulisher
Nov 20, 2024

Voyager's New Alzheimer's Gene Therapy Shows 73% Tau Reduction in Key Study | VYGR Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 18, 2024

Voyager Therapeutics’ TRACER Platform Targets CNS Market: Here’s Why I’m Neutral (VYGR) - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

StockNews.com Upgrades Voyager Therapeutics (NASDAQ:VYGR) to "Buy" - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 Earnings Forecast for VYGR Issued By HC Wainwright - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at Canaccord Genuity Group - Defense World

Nov 17, 2024
pulisher
Nov 17, 2024

Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

When the Price of (VYGR) Talks, People Listen - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 15, 2024

Voyager Therapeutics stock hits 52-week low at $5.71 - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

EcoR1 Capital, LLC Increases Stake in Voyager Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Leerink Partnrs Has Negative Outlook of VYGR FY2024 Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Voyager Therapeutics' (VYGR) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Voyager Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

Nov 14, 2024
pulisher
Nov 14, 2024

Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)? - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Earnings call: Voyager Therapeutics focuses on neurological therapies By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

Voyager Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 13, 2024
pulisher
Nov 13, 2024

Voyager Therapeutics Inc earnings beat by $0.29, revenue topped estimates - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

Voyager Therapeutics Reports Strong Q3 2024 Progress - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings: Revenue Soars to $24.63M, EPS Loss of $0.16 Beats Estimates - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Voyager Reports Third Quarter 2024 Financial and Operating Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Voyager Therapeutics Revenue Soars 435% in Q3, Secures $15M Novartis Deal | VYGR Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada

Nov 12, 2024
pulisher
Nov 10, 2024

Voyager Therapeutics (NASDAQ:VYGR) Cut to Hold at StockNews.com - MarketBeat

Nov 10, 2024
pulisher
Nov 08, 2024

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve

Nov 08, 2024
pulisher
Nov 06, 2024

Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Voyager Therapeutics to Present at 4 Major Healthcare Investor Conferences in November | VYGR Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

VYGRVoyager Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Voyager Therapeutics (VYGR) to Report Q3 2024 Earnings on November 12 | VYGR Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Learn to Evaluate (VYGR) using the Charts - Stock Traders Daily

Nov 05, 2024
pulisher
Nov 04, 2024

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength? - MSN

Nov 04, 2024
pulisher
Nov 02, 2024

Voyager Therapeutics (NASDAQ:VYGR) Rating Increased to Buy at StockNews.com - MarketBeat

Nov 02, 2024
pulisher
Oct 28, 2024

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Canada Finance

Oct 28, 2024
pulisher
Oct 28, 2024

Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $17.43 - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Analysts - Defense World

Oct 28, 2024
pulisher
Oct 27, 2024

Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Lowered by StockNews.com - Defense World

Oct 27, 2024
pulisher
Oct 26, 2024

StockNews.com Lowers Voyager Therapeutics (NASDAQ:VYGR) to Hold - MarketBeat

Oct 26, 2024
pulisher
Oct 25, 2024

How to Take Advantage of moves in (VYGR) - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 24, 2024

HC Wainwright Reaffirms Buy Rating for Voyager Therapeutics (NASDAQ:VYGR) - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Viral Vectors-Based Gene Therapy for Non-Human Primates Market - openPR

Oct 22, 2024
pulisher
Oct 18, 2024

Equities Analysts Offer Predictions for VYGR Q3 Earnings - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Voyager Therapeutics (NASDAQ:VYGR) Rating Increased to Strong-Buy at Leerink Partnrs - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Voyager Therapeutics (NASDAQ:VYGR) Upgraded to "Strong-Buy" by Leerink Partnrs - MarketBeat

Oct 17, 2024

Voyager Therapeutics Inc Stock (VYGR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):